RESUMEN
Gentamicin C1a is an important precursor to the synthesis of etimicin, a potent antibiotic. Wild type Micromonospora purpurea Gb1008 produces gentamicin C1a, besides four other gentamicin C components: C1, C2, C2a, and C2b. While the previously reported engineered strain M. purpurea GK1101 can produce relatively high titers of C1a by blocking the genK pathway, a small amount of undesirable C2b is still being synthesized in cells. Gene genL (orf6255) is reported to be responsible for converting C1a to C2b and C2 to C1 in Micromonospora echinospora ATCC15835. In this work, we identify the genL that is also responsible for the same methylation in Micromonospora purpurea. Based on M. purpurea GK1101, we construct a new strain with genL inactivated and show that no C2b is produced in this strain. Therefore, we successfully engineer a strain of M. purpurea that solely produces gentamicin C1a. This strain can potentially be used in the industrial production of C1a for the synthesis of etimicin.
RESUMEN
Tobramycin is an important broad spectrum aminoglycoside antibiotic widely used against severe Gram-negative bacterial infections. It is produced by base-catalyzed hydrolysis of carbamoyltobramycin (CTB) generated by S. tenebrarius. We herein report the construction of a genetically engineered S. tenebrarius for direct fermentative production of tobramycin by disruption of aprK and tobZ. A unique putative NDP-octodiose synthase gene aprK was disrupted to optimize the production of CTB, resulting in the blocking of apramycin biosynthesis and the obvious increase in CTB production of aprK disruption mutant S. tenebrarius ST316. Additional mutation on the carbamoyltransferase gene tobZ in S. tenebrarius ST316 generated a strain ST318 that produces tobramycin as a single metabolite. ST318 could be used for industrial fermentative production of tobramycin.
Asunto(s)
Vías Biosintéticas/genética , Ingeniería Metabólica , Streptomyces/genética , Streptomyces/metabolismo , Tobramicina/biosíntesis , Proteínas Bacterianas/genética , Fermentación , Técnicas de Inactivación de GenesRESUMEN
Gentamicin and sisomicin are two different aminoglycoside antibiotics. The comparison of their chemical structure and biosynthetic gene clusters, coupled with bioinformatic analysis, suggested that the gntK gene would be associated with methylation. The gntK gene fragment in M. purpurea G1008 was inactivated by genetic engineering and its mutant strain M. purpurea GK1101 (ΔgntK) was screened. The metabolites of G1008 and GK1101 was analyzed by HPLC-MS, which revealed that GK1101 no longer produced gentamicin C(1) or C(2), while mainly synthesizing gentamicin C(1a), and the production of C(1a) increased significantly. This indicated that the metabolic flow for the gentamicin C(1) and C(2) biosynthesis was blocked by disrupting the gntK gene, which substantiated that the gntK gene encoded the enzyme that catalyzes the methylation of purpurosamine C-6'. The mutant GK1101 has good prospects for industrial application. In addition, our study provides information that can be used to clarify the function of a single gene and simplify the targeted genetic breeding of important pharmaceutical microorganisms.
Asunto(s)
Genes Bacterianos , Gentamicinas/biosíntesis , Heptosas/metabolismo , Micromonospora/genética , Dominio Catalítico , Conjugación Genética , Escherichia coli/metabolismo , Fermentación , Metilación , Micromonospora/metabolismo , Peso Molecular , Plásmidos/genética , Plásmidos/metabolismo , Activación TranscripcionalRESUMEN
Micromonospora inyoensis produces sisomicin (Sm), an aminoglycoside antibiotic. The gene cluster of sisomicin biosynthesis spanning ca. 47 kb consists of 37 ORFs encoding various proteins for sisomicin biosynthesis, regulation, resistance and transport. The comparative genetic studies on the biosynthetic genes of sisomicin and gentamicin (Gm) reveal a similar biosynthetic route and provide a framework for the future biosynthetic studies.
Asunto(s)
Vías Biosintéticas , Micromonospora/genética , Familia de Multigenes , Sisomicina/biosíntesis , Antibacterianos/biosíntesis , Clonación Molecular , Orden Génico , Análisis de Secuencia de ADN , SinteníaRESUMEN
A new sisomicin resistance gene sisR was cloned from sisomicin-producing Micromonospora inyoensis. The sisR fragment was obtained by PCR amplification. The primer pairs were designed based on grm gene sequence from gentamicin-producing Micromonospora purpurea. The template DNA was isolated from Micromonospora inyoensis. A series of different DNA fragments were amplified by PCR, which were sub-cloned to vector pUC19 for further identification. It was found that five specific transformants containing target DNA fragments could resist high concentrations of sisomicin (over 1000 microg/mL sisomicin). One of them designated as sisR, was then sequenced and the alignment among sisR and other related genes showed that sisR gene differs from any known genes. It was concluded that sisR gene is a sequence that has not been reported so far.